Sepsis kills approximately 11 million people annually and accounts for one in five deaths worldwide. The core challenge is time: every hour of delayed diagnosis increases mortality by 7%. Current detection relies on blood draws, lab cultures, and clinical observation, a process that takes 24–72 hours. BioSentinel is a disposable, non-invasive wearable patch that detects sepsis-associated biomarkers in interstitial fluid and sweat up to 12 hours before clinical symptoms manifest.

How it works: The patch is a 6 cm × 4 cm flexible multilayer device worn on the inner forearm. Its underside contains an array of microneedle electrodes, 200-micron-length solid silicon microneedles that painlessly breach the stratum corneum to access interstitial fluid without drawing blood. Each electrode is functionalized with a specific aptamer (synthetic DNA/RNA strand) targeting one of four biomarkers: lactate (cellular hypoxia indicator), interleukin-6 (early inflammatory cytokine), procalcitonin (bacterial infection marker), and cortisol (stress immune response). Electrochemical impedance spectroscopy reads binding events in real time, translating molecular concentration changes into continuous electrical signals. An onboard microcontroller applies a trained gradient boosting ML model to the four-channel biomarker stream, generating a sepsis risk score updated every 15 minutes. When risk crosses a validated threshold, the patch vibrates and transmits an alert via Bluetooth Low Energy to nursing station monitors and clinical apps.

What makes it novel: Existing wearable biosensors target single biomarkers (glucose, lactate) for chronic disease management. BioSentinel is the first quadruplex aptamer-based patch designed specifically for acute infection triage. The multi-biomarker fusion model was trained on 40,000 ICU patient records, giving it sensitivity of 91% and specificity of 88% in retrospective validation, significantly outperforming individual biomarker thresholds.

Manufacturing: The microneedle array is fabricated via deep reactive ion etching of silicon wafers, then coated with gold via sputtering deposition and functionalized with aptamers in a roll-to-roll wet chemistry process. The flexible substrate uses polyimide. The entire patch is assembled in cleanroom conditions similar to existing glucose patch manufacturing lines (Abbott, Dexcom). Unit cost at scale is estimated at $18–$24 per patch, which is trivial against the $32,000 average cost of a sepsis ICU admission.

Where it's applied: Primary deployment in hospital ICUs, emergency departments, and post-surgical wards, settings where patients are at highest risk and continuous monitoring is standard of care. Secondary market: emergency triage in low-resource settings and rural clinics where lab turnaround time is a critical bottleneck. A consumer-facing version for immunocompromised patients (chemotherapy, organ transplant recipients) represents a third growth market.

Market potential: The global sepsis diagnostics market is projected at $1.2B by 2028. A wearable, continuous, non-invasive solution at sub-$25 unit cost positions BioSentinel to capture significant share while simultaneously reducing downstream ICU costs, a compelling value proposition for hospital procurement and insurance reimbursement alike.